Terapevticheskii arkhivTerapevticheskii arkhiv0040-36602309-5342LLC Obyedinennaya Redaktsiya3281210.26442/terarkh2018906121-129Review ArticleChronic kidney disease as a multidisciplinary problem of contemporary medicinePodzolkovV I-BraginaA Eanna.bragina@mail.ruI.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)1506201890612112911042020Copyright © 2018, Consilium Medicum2018A review deals with the problem of chronic kidney disease (CKD) from the position of a physician and cardiologist. The epidemiology of the disease was discussed both abroad and in Russia, including the most up-to-date data. In Russia CKD markers were detected in 49.4% of hypertensives. Authors describe risk factors and mechanisms of CKD at the most important pathogenetic conditions: hypertension, diabetes and obesity. The current classification and methods for calculating the glomerular filtration rate are given. The review disclose a paradigm of the renal continuum and its relation to cardiovascular diseases. It is well known fact that the final causes of the death of patients with CKD, as a rule, are cardiovascular complications. Based on the literature data, the necessity and expediency of screening for renal dysfunction is justified. In the example of use of an angiotensin receptor blocker II - irbesartan nephroprotective demonstrated possibilities of intervention in patients with renal dysfunction of varying severity.chronic kidney diseaserenal continuumnephroprotectionangiotensin II receptor blockersхроническая болезнь почекпочечный континуумнефропротекцияблокатор рецепторов ангиотензина II[Pippias M. The European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2014: a summary. Clin Kidney J. 2017;10:1-10. doi: 10.1093/ckj/sfw135][Tomson C.R, Foley R.N, Li Q, Gilbertson D.T, Xue J.L, Collins A.J. Race and end - stage renal disease in the United States Medicare population: the disparity persists. Nephrology (Carlton). 2008 Oct;13(7):651-6. doi: 10.1111/j.1440-1797.2008.01010.x][2017 USRDS Annual Data Report: Executive Summary. Am J Kidney Dis. 2018;71(3 Suppl. 1):S1-S8. doi: 10.1053/j.ajkd.2018.01.003][Jager K.J, Ocak G, Drechsler C, et al. The EQUAL study: a European study in chronic kidney disease stage 4 patients. Nephrol Dial Transplant. 2012;27(Suppl. 3):iii27-iii31. doi: 10.1093/ndt/gfs277. Epub 2012 Jul 4.][Caskey F.J, Jager K.J. A population approach to renal replacement therapy epidemiology: lessons from the EVEREST study. Nephrol Dial Transplant. 2014;29:1494-9. doi: 10.1093/ndt/gft390. Epub 2013 Oct 28.][Ощепкова Е.В., Долгушева Ю.А., Жернакова Ю.В. и др. Распространенность нарушения функции почек при артериальной гипертонии (по данным эпидемиологического исследования ЭССЕ-РФ). Системные гипертензии. 2015;12(3):19-24.][Нагайцева С.С., Швецов М.Ю., Герасимов А.Н. и др. Исследование альбуминурии как маркера хронической болезни почек у взрослого трудоспособного населения. Альманах клинической медицины. 2014;(30):37-45.][Кобалава Ж.Д., Виллевальде С.В., Боровкова Н.Ю., Шутов А.М., Ничик Т.Е., Сафуанова Г.Ш. от имени исследователей программы ХРОНОГРАФ. Распространенность маркеров хронической болезни почек у пациентов с артериальной гипертонией: результаты эпидемиологического исследования ХРОНОГРАФ. Кардиология. 2017;57(10):39-44. doi: 10.18087/cardio.2017.10.10041][Моисеев B.C., Мухин Н.А., Смирнов А.В. и др. Национальные рекомендации. Сердечно - сосудистый риск и хроническая болезнь почек: стратегии кардио - нефропротекции. 2013. Клиническая фармакология и терапия. 2014;23(3):4-27.][Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3(1):1-150.][Смирнов А.В., Шилов Е.М., Добронравов В.А., Каюков И.Г. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Санкт-Петербург: Левша; 2012. С. 54.][Chronic Kidney Disease Prognosis Consortium; Matsushita K, van der Velde M, Astor B.C, Woodward M, et al. Association of estimated glomerular filtration rate and albuminuria with all - cause and cardiovascular mortality in general population cohorts: a collaborative meta - analysis. Lancet. 2010;375(9731):2073-81. doi: 10.1016/S0140-6736(10)60674-5. Epub 2010 May 17.][Van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all - cause and cardiovascular mortality. A collaborative meta - analysis of high - risk population cohorts. Kidney Int. 2011;79(12):1341-52. doi: 10.1038/ki.2010.536. Epub 2011 Feb 9.][Levey A.S, de Jong P.E, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80(1):17-28. doi: 10.1038/ki. 2010.483. Epub 2010 Dec 8.][Levey A.S, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139(2):137-47.][Hallan S.I, Ritz E, Lydersen S, Romundstad S, Kvenild K, Orth S.R. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol. 2009 May;20(5):1069-77. doi: 10.1681/ASN.2008070730. Epub 2009 Apr 8.][Eriksen B, Ingebretsen O. The progression of chronic kidney disease: a 10-year population - based study of the effects of gender and age. Kidney Int. 2006;69:375-82.][Mc Cullough P.A. CKD and cardiovascular disease in screened high - risk volunteer and general populations: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis. 2008;51(4 Suppl. 2):S38-S45. doi: 10.1053/j.ajkd.2007.12.017][Chrysohoou C. Renal function, cardiovascular disease risk factors’ prevalence and 5-year disease incidence: the role of diet, exercise, lipids and inflammation markers: the ATTICA study. QJM. 2010;103:413-22. doi: 10.1093/qjmed/hcq045. Epub 2010 Apr 7.][Yu M.K. Risk Factor, age and sex differences in chronic kidney disease prevalence in a diabetic cohort: the pathways study. Am J Nephrol. 2012;36(3):245-61. doi: 10.1159/000342210. Epub 2012 Sep 4.][Daugherty S.L. Sex differences in cardiovascular outcomes in patients with incident hypertension. J Hypertens. 2013;31(2):271-7. doi: 10.1097/HJH.0b013e32835bdc44][Warmoth L, Regalado M.M, Simoni J, et al. Cigarette smoking enhances increased urine albumin excretion as a risk factor for glomerular filtration rate decline in primary hypertension. Am J Med Sci. 2005;330(3):111-9.][Подзолков В.И., Брагина А.Е., Родионова Ю.Н. Влияние табакокурения на состояние почечной и центральной гемодинамики у мужчин и женщин с эссенциальной артериальной гипертензией. Кардиоваскулярная терапия и профилактика. 2009;8(6):10-5.][Atkins R.C. The epidemiology of chronic kidney disease. Kidney Int. 2005;67(94):14-8.][Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III). J Am Soc Nephrol. 2002;13(5):1338-49.][Böhm M, Thoenes M, Danchin N, et al. Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the iSEARCH global study. J Hypertens. 2007;25(11):2317-24.][Маслова О.В., Сунцов Ю.И., Шестакова М.В., Казаков И.В., Викулова О.К., Сухарева О.Ю., Мартынов С.А. Распространенность диабетической нефропатии и хронической болезни почек при сахарном диабете в Российской Федерации. Клиническая нефрология. 2010;(3):45-51.][Luke R.G. Hypertensive nephrosclerosis: pathogenesis and prevalence. Essential hypertension is an important cause of end - stage renal disease. Nephrol Dial Transplant. 1999;14(10):2271-8.][Hill G.S. Hypertensive nephrosclerosis. Curr Opin Nephrol Hypertens. 2008;17(3):266-70.][Ritz E, Orth S, Weinreich T, Wagner J. Systemic hypertension versus intraglomerular hypertension in progression. Kidney Int. 1994;45 (2):438-42.][Herrera-Acosta J. The role of systemic and glomerular hypertension in progressive glomerular injury. Kidney Int Suppl. 1994;45:S6-10.][Burns K.D. Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis. 2000;36(3):449-67.][Sharma A.M. Renal involvement in hypertensive cardiovascular disease. Eur Heart J. 2003;5(Suppl F):F12-F8.][Ritz E, Amann K, Fliser D. The sympathetic nervous system and the kidney: its importance in renal diseases. Blood Press. 1998; Suppl 3:14-9.][Williams J.D, Coles G.A. Proteinuria - a direct cause of renal morbidity? Kidney Int. 1994;45(2):443-50.][Keane W.F. Lipids and the kidney. Kidney Int. 1994;46(3):910-20.][Подзолков В.И., Булатов В.А. Миокард. Нефрон. Взгляд через призму эволюции артериальной гипертензии. Русский медицинский журнал. 2008;16(11):1517-23.][Климонтов В.В., Мякина Н.Е. Хроническая болезнь почек при сахарном диабете. Новосибирск: Издательство НГУ; 2014. 44 c.][Шестакова М.В. Сахарный диабет и хроническая болезнь почек: современная диагностика и лечение. Вестник РАМН. 2012;(1):45-9.][Otu H.H, Can H, Spentzos D, et al. Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care. 2007;30(3):638-43.][Краснова Е.А., Моисеев С.В., Фомин В.В. Нефрологические аспекты проблемы ожирения. Клиническая медицина. 2005;(4):8-13.][Подзолков В.И., Брагина А.Е., Родионова Ю.Н. Гендерные особенности микроальбуминурии и ее взаимосвязь с показателями внутрипочечной гемодинамики и уровнем лептина у больных артериальной гипертензией. Рациальная фармакотерапия в кардиологии. 2012;8(1):31-6.][Подзолков В.И., Булатов В.А. Гипертонические изменения почек. В кн.: Подзолков В.И. Артериальная гипертензия. Москва: МИА; 2016. С. 170-202.][Мухин Н.А., Моисеев В.С., Кобалава Ж.Д., Моисеев С.В., Фомин В.В. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно - сосудистой системы и почек. Терапевтический архив. 2004;(6):39-47.][Ronco C, Mc Cullough P, Anker S.D, et al. Cardio - renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J. 2010;31(6):703-11. doi: 10.1093/eurheartj/ehp507. Epub 2009 Dec 25.][Ronco C, Ronco F. Cardio - renal syndromes: a systematic approach for consensus definition and classification. Heart Failure Reviews. 2012;17(2):151-60. doi: 10.1007/s10741-010-9224-0][Fernandez-Fernandez O, Garcia-Trujillo L, Guerrero-Fernandez M, et al. The effectiveness of glatiramer acetate in clinical practice: an observational study. Revista de Neurologia. 2012;54(1):1-9.][Zhang Q.L, Rothenbacher D. Prevalence of chronic kidney disease in population based studies: systematic review. BMC Public Health. 2008;8:117-24. doi: 10.1186/1471-2458-8-117][Coresh J, Selvin E, Stevens L.A, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2011;298:2038-47.][Zoccali C, Kramer A, Jager K.J. Epidemiology of CKD in Europe: an uncertain scenario. Nephrol Dial Transplant. 2010;25:1731-3. doi: 10.1093/ndt/gfq250][Parving H.H, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870-8.][Lewis E.J, Hunsicker L.G, Clarke W.R, et al. Collaborative Study Group. Renoprotective effect of the angiotensin - receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-60.][Hallan S.I, Dahl K, Oien C.M, Grootendorst D.C, Aasberg A, Holmen J, Dekker F.W. Screening strategies for chronic kidney disease in the general population: follow - up of cross sectional health survey. BMJ. 2006 Nov 18;333(7577):1047.]